Literature DB >> 25442931

Translating human genetics into novel treatment targets for schizophrenia.

Christian R Schubert1, Hualin S Xi2, Jens R Wendland3, Patricio O'Donnell4.   

Abstract

Human genetics is a rational starting point for target identification in drug discovery, yet this approach has found little application in neuroscience. Recent large-scale analyses have begun to identify robust genetic loci for schizophrenia, providing an opportunity to derive novel drug targets. Here, we summarize a strategy for applying human genetics to neuroscience drug discovery.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2014        PMID： 25442931     DOI： 10.1016/j.neuron.2014.10.037

Source DB:  PubMed          Journal:  Neuron        ISSN： 0896-6273            Impact factor:   17.173


  10 in total

Review 1.  Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies.

Authors:  Colm M P O'Tuathaigh; Paula M Moran; Xuechu C Zhen; John L Waddington
Journal:  Br J Pharmacol       Date:  2017-08-03       Impact factor: 8.739

Review 2.  Sensorimotor gating deficits in "two-hit" models of schizophrenia risk factors.

Authors:  Asma Khan; Susan B Powell
Journal:  Schizophr Res       Date:  2017-10-22       Impact factor: 4.939

Review 3.  Translating genome-wide association findings into new therapeutics for psychiatry.

Authors:  Gerome Breen; Qingqin Li; Bryan L Roth; Patricio O'Donnell; Michael Didriksen; Ricardo Dolmetsch; Paul F O'Reilly; Héléna A Gaspar; Husseini Manji; Christopher Huebel; John R Kelsoe; Dheeraj Malhotra; Alessandro Bertolino; Danielle Posthuma; Pamela Sklar; Shitij Kapur; Patrick F Sullivan; David A Collier; Howard J Edenberg
Journal:  Nat Neurosci       Date:  2016-10-26       Impact factor: 24.884

Review 4.  New drug developments in psychosis: Challenges, opportunities and strategies.

Authors:  Matcheri S Keshavan; Ashley N Lawler; Henry A Nasrallah; Rajiv Tandon
Journal:  Prog Neurobiol       Date:  2016-08-09       Impact factor: 11.685

5.  Schizophrenia-Associated hERG channel Kv11.1-3.1 Exhibits a Unique Trafficking Deficit that is Rescued Through Proteasome Inhibition for High Throughput Screening.

Authors:  Nicholas E Calcaterra; Daniel J Hoeppner; Huijun Wei; Andrew E Jaffe; Brady J Maher; James C Barrow
Journal:  Sci Rep       Date:  2016-02-16       Impact factor: 4.379

6.  A group II metabotropic glutamate receptor 3 (mGlu3, GRM3) isoform implicated in schizophrenia interacts with canonical mGlu3 and reduces ligand binding.

Authors:  Aintzane García-Bea; Isabel Bermudez; Paul J Harrison; Tracy A Lane
Journal:  J Psychopharmacol       Date:  2017-06-28       Impact factor: 4.153

Review 7.  Molecular mechanisms underlying noncoding risk variations in psychiatric genetic studies.

Authors:  X Xiao; H Chang; M Li
Journal:  Mol Psychiatry       Date:  2017-01-03       Impact factor: 15.992

8.  Strategies to Address Challenges in Neuroscience Drug Discovery and Development.

Authors:  Patricio O'Donnell; Laura Rosen; Robert Alexander; Venkatesha Murthy; Ceri H Davies; Emiliangelo Ratti
Journal:  Int J Neuropsychopharmacol       Date:  2019-07-01       Impact factor: 5.176

9.  The effect of a genetic variant at the schizophrenia associated AS3MT/BORCS7 locus on striatal dopamine function: A PET imaging study.

Authors:  Enrico D'Ambrosio; Tarik Dahoun; Antonio F Pardiñas; Mattia Veronese; Michael A P Bloomfield; Sameer Jauhar; Ilaria Bonoldi; Maria Rogdaki; Sean Froudist-Walsh; James T R Walters; Oliver D Howes
Journal:  Psychiatry Res Neuroimaging       Date:  2019-07-19       Impact factor: 2.376

10.  Polymorphisms in Dopaminergic Genes in Schizophrenia and Their Implications in Motor Deficits and Antipsychotic Treatment.

Authors:  Jiaen Ye; Feng Ji; Deguo Jiang; Xiaodong Lin; Guangdong Chen; Wei Zhang; Peiwei Shan; Li Zhang; Chuanjun Zhuo
Journal:  Front Neurosci       Date:  2019-04-17       Impact factor: 4.677
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.